Our preclinical data set the bases for utilizing CD4-directed CAR T cells and CAR NK cells as a novel and effective treatment for patients with refractory CD4 + AML to eliminate residual disease as a bridge to more definitive therapy with allogeneic SCT. This evidence concerns the gene CD4 and acute myeloid leukemia.